France· FR:67336111
RIVAROXABAN ARROW 10 mg, comprimé pelliculé
A medicinal product containing rivaroxaban, registered in France by ARROW GENERIQUES, on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- RIVAROXABAN
- Manufacturer
- ARROW GENERIQUES
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
1 priced- cip133400930156032plaquette(s) PVC PVDC aluminium de 30 comprimé(s)EUR 13.25
- cip133400955058083plaquette(s) PVC PVDC aluminium de 100 comprimé(s)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Rivaroxaban in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAXALTRA+pharma arzneimittel gmbh, Graz
- SpainCOAGUBAN 10 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGTowa Pharmaceutical Europe S.L.
- PolandAxaltrapharma arzneimittel gmbh
- SwitzerlandRivarax 10 mg, FilmtablettenDrossapharm AG
- NetherlandsBlomensy 10 mg filmomhulde tablettenEgis Pharmaceuticals Plc
- SwedenBevimlar 10 mg Filmdragerad tablettSTADA Arzneimittel AG
- ItalyMIREBAXAURORA LICENSING S.R.L.
- FinlandDovequaBausch Health Ireland Limited
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Rivahib, Rivaroksaban Grindeks
- Belgium · Rivaroxaban, Rivaroxaban Eg
- Bulgaria · Xaboplax Sandoz Pharmaceuticals D.D, Виатрикс
- Cyprus · Enkia, Naxat
- Czechia · Axaltra, Bevimlar
- Germany · Elmardya, Rivadia
- Denmark · Blomensy, Dovequa
- Estonia · Enkia, Kardatuxan
- Spain · Blomensy, Elmardya
- Finland · Blomensy, Dovequa
- United Kingdom (Northern Ireland) · Rivaroxaban, Rivaroxaban Abdi
- Greece · Blomensy, Cinstel
- Croatia · Aban, Bevimlar
- Hungary · Dovequa, Evoxyr
- Ireland · Rivaroxaban Ascend, Rivaroxaban Azure
- Iceland · Agublon, Barsovi
- Italy · Ellebax, Indifaxa
- Liechtenstein · Rivaroxaban Accord, Rivaroxaban Viatris
- Lithuania · Enkia, Kardatuxan
- Luxembourg · Rivaroxaban Eg, Rivaroxaban Eg (Eurogenerics) Nv
- Latvia · Kardatuxan, Mibrex
- Malta · Enkia, Naxat
- Netherlands · Blomensy, Rivaroksaban Grindeks
- Norway · Dovequa, Rivaroxaban Accord
- Poland · Axaltra, Bevimlar
- Portugal · Closderive, Enkia
- Romania · Closderive, Enkia
- Sweden · Bevimlar, Blomensy
- Slovenia · Dovequa, Ribas
- Slovakia · Assubex, Bevimlar
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c044a3d2-e4b1-41e7-9fdc-4d17e563b545 GET /v1/drugs/c044a3d2-e4b1-41e7-9fdc-4d17e563b545?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "67336111",
"date_amm": "2018-08-08",
"type_amm": "Procédure décentralisée",
"numero_ue": null,
"substance": "RIVAROXABAN",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about rivaroxaban.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.